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Introduction {#ner12267-sec-0005}
============

Hemiplegic migraine (HM) is a rare but particularly severe form of migraine that is distinguished by its associated motor aura. The International Classification of Headache Disorders II (ICHD II) recognizes two subtypes, familial HM and sporadic HM, which are similar clinically and differ only in familial associations [1](#ner12267-bib-0001){ref-type="ref"}. Though uncommon, it is the most debilitating form of the disease and often progresses to an incapacitating situation resistant to medical management [2](#ner12267-bib-0002){ref-type="ref"}, [3](#ner12267-bib-0003){ref-type="ref"}, [4](#ner12267-bib-0004){ref-type="ref"}. Recognition of the magnitude of its impact on society has galvanized a search for more effective therapies, an end to which guidance is provided by evidence that HM has mechanisms and therapies in common with other migraine types [2](#ner12267-bib-0002){ref-type="ref"}, [5](#ner12267-bib-0005){ref-type="ref"}, [6](#ner12267-bib-0006){ref-type="ref"}. On the basis of these common features we felt that other documented migraine therapies, including implanted peripheral neurostimulation (PNS), might also benefit HM.

PNS therapy for headache (HA) may be divided into two categories according to paresthesia concordancy, where a concordant paresthesia is defined as one that optimally covers the anatomic area of perceived pain [7](#ner12267-bib-0007){ref-type="ref"}, [8](#ner12267-bib-0008){ref-type="ref"}. Examples of the "concordant paresthesia" category include the application of occipital nerve stimulation (ONS) to occipital neuralgia, supraorbital nerve stimulation (SONS) to supraorbital neuralgia, and combined occipital and supraorbital neurostimulation (ON‐SONS) to patients with holocephalic pain due chronic migraine. Typifying the "non‐concordant paresthesia" category is the application of ONS to any migraine pain perceived over the distant fronto‐temporal (trigeminal) region. There is some preliminary evidence that suggests a higher success rate for implants that produce a concordant paresthesia (Tables [1](#ner12267-tbl-0001){ref-type="table-wrap"} and [2](#ner12267-tbl-0002){ref-type="table-wrap"}) [7](#ner12267-bib-0007){ref-type="ref"}.

###### 

Summary of Primary Headache Diagnostic Categories Treated with Non‐concordant Neurostimulation

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Report                                                                                                              Dx   Stim   No perms   No responders   Resp rate
  ------------------------------------------------------------------------------------------------------------------- ---- ------ ---------- --------------- -------------
  Cluster Treated with ONS Alone                                                                                                                             

  Dodick [9](#ner12267-bib-0009){ref-type="ref"}                                                                      Cl   ONS    1          1               100%

  Burns [10](#ner12267-bib-0010){ref-type="ref"}, [11](#ner12267-bib-0011){ref-type="ref"}                            Cl   ONS    20         9               45%

  Magis [12](#ner12267-bib-0012){ref-type="ref"}                                                                      Cl   ONS    14         12              85%

  Trentman [13](#ner12267-bib-0013){ref-type="ref"}                                                                   Cl   ONS    5          3               60%

  Schwedt [14](#ner12267-bib-0014){ref-type="ref"}                                                                    Cl   ONS    8          5               60%

  de Quintana [15](#ner12267-bib-0015){ref-type="ref"}                                                                Cl   ONS    4          4               100%

  Fontaine [16](#ner12267-bib-0016){ref-type="ref"}                                                                   Cl   ONS    13         10              77%

  Mueller [17](#ner12267-bib-0017){ref-type="ref"}                                                                    Cl   ONS    10         4               [40%]{.ul}

                                                                                                                                                             **64% avg**

  Chronic Migraine Treated with ONS Alone                                                                                                                    

  Saper (Medtronic) [18](#ner12267-bib-0018){ref-type="ref"}                                                          CM   ONS    51         ?               39%

  Silberstein; Dodick (St. Jude) [19](#ner12267-bib-0019){ref-type="ref"}, [20](#ner12267-bib-0020){ref-type="ref"}   CM   ONS    157        20              48%

  Lipton (Boston Scientific) [21](#ner12267-bib-0021){ref-type="ref"}                                                 CM   ONS    132        ?               ?

  Paemeliere [22](#ner12267-bib-0022){ref-type="ref"}                                                                 CM   ONS    8          5               63%

  Brewer [23](#ner12267-bib-0023){ref-type="ref"}                                                                     CM   ONS    12         5               42%

  Palmisani [24](#ner12267-bib-0024){ref-type="ref"}                                                                  CM   ONS    17         9               [53%]{.ul}

                                                                                                                                                             **47% avg**

  **Summary: 51% avg for all non‐concordant studies (CM & Cl)**\                                                                                             
  **47% avg for all CM studies (excludes Lipton)**                                                                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The Medtronic study used a VAS improvement of 30% as the test for positive response, rather than the historical standard of 50%.

The statistics from the St. Jude Study Group\'s reports (Silberstein [20](#ner12267-bib-0020){ref-type="ref"}; Dodick [19](#ner12267-bib-0019){ref-type="ref"}) come from the Dodick [19](#ner12267-bib-0019){ref-type="ref"} report.

Table 1 is an update on a table from a previous report of our group [7](#ner12267-bib-0007){ref-type="ref"}.

Cl, cluster; CM, chronic migraine; HC, hemicrania continua.
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###### 

Summary of All Primary Headache Categories Treated with Concordant Neurostimulation

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Report                                                                                   Dx   Stim                  No perm   No responders   Resp rate
  ---------------------------------------------------------------------------------------- ---- --------------------- --------- --------------- --------------
  Occipitally Focused Primary HA Treated with ONS Alone                                                                                         

  Popeney, Aló [25](#ner12267-bib-0025){ref-type="ref"}                                    TM   ONS                   25        25              100%

  Oh [26](#ner12267-bib-0026){ref-type="ref"}                                              TM   ONS                   10        9               90%

  Matharu [27](#ner12267-bib-0027){ref-type="ref"}                                         CM   ONS                   8         [8]{.ul}        [100%]{.ul}

                                                                                                                                                **98% avg**

  Frontal Primary HA Treated with Trigeminal Stim Alone                                                                                         

  Narouze [28](#ner12267-bib-0028){ref-type="ref"}                                         Cl   SON                   1         1               100%

  Vaisman [29](#ner12267-bib-0029){ref-type="ref"}                                         Cl   SON                   5         5               100%

  Simopoulos [30](#ner12267-bib-0030){ref-type="ref"}                                      CM   AT                    1         [1]{.ul}        [100%]{.ul}

                                                                                                                                                **100% avg**

  Hemicephalic/Holocephalic Primary HA Treated with Combined Stim                                                                               

  Reed [31](#ner12267-bib-0031){ref-type="ref"}                                            CM   ON‐SON                7         7               100%

  Deshpande [32](#ner12267-bib-0032){ref-type="ref"}                                       CM   ON‐ATN                1         1               100%

  Hahn [33](#ner12267-bib-0033){ref-type="ref"}                                            CM   ON‐SON                14        10              70%

  Mammis [34](#ner12267-bib-0034){ref-type="ref"}                                          Cl   ON‐SON‐ION            1         1               100%

  Zach [35](#ner12267-bib-0035){ref-type="ref"}                                            CM   ON‐ATN                1         [1]{.ul}        [100%]{.ul}

                                                                                                                                                **83% avg**

  Mixed Regional/Hemicephalic/Holocephalic Primary HA Treated with Mixed Concordant Stim                                                        

   Verrills [36](#ner12267-bib-0036){ref-type="ref"}                                       CM   ON; SON; ON‐SON/ION   60        [7]{.ul}        [68%]{.ul}

                                                                                                                                                **68% avg**

  **Summary: 82% avg response for all concordant studies**\                                                                                     
  **81% avg response for CM studies**                                                                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

The Popeney and Oh reports on transformed migraine were expressly on patient groups whereby the pain was solely or primarily focused over the occipital region.

Unless otherwise specified all success rates indicate \> 50% improvement in VAS or HA freq.

Table 2 is an update of a table from a previous report from our group [7](#ner12267-bib-0007){ref-type="ref"}.

TM, transformed migraine; CEH, cervicogenic headache; IC2H, intractable C‐2 Headaches; AC, Arnold‐Chiari; CM, chronic migraine; CNP, cervical neuropathic pain; TNP, trigeminal neuropathic pain; AFP, atypical facial pain; PHN, post herpetic neuralgia; SON, supraorbital nerve; ATN, auriculotemporal nerve; ION, infraorbital nerve; ON, occipital nerve.
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Based upon these considerations, we felt that concordant combined ON‐SONS may have potential as a therapy for HM. While previous studies have documented PNS efficacy across a wide range of primary HA diagnostic categories, including two papers that reported resolution of hemiplegia as an associated finding, this is the first to specifically consider its potential as a therapy for HM [31](#ner12267-bib-0031){ref-type="ref"}, [32](#ner12267-bib-0032){ref-type="ref"}.

Materials and Methods {#ner12267-sec-0006}
=====================

As our center does not have a formal ethics review committee, we note that the procedures involved in the evaluation and treatment of all patients, including full oral and written informed consent, were part of the normal procedures applied to all patients in the physicians\' offices. Further, all aspects of patient care specifically conformed to the ethical principles for human subjects as outlined in the Declaration of Helsinki.

Between 2004 and 2013 five patients suffering from debilitating, chronic HM were referred to our facility for evaluation for implantable PNS. All had been under the care of experienced neurology headache specialists, who for each patient had documented an extensive diagnostic evaluation, including laboratory and imaging studies to rule out other causes of chronic head pain. No genetic testing was undertaken for the recognized gene mutations associated with familial HM; however, the family histories of all the patients were specifically negative for HM [37](#ner12267-bib-0037){ref-type="ref"}. All diagnoses conformed to ICHD II criteria for HM [1](#ner12267-bib-0001){ref-type="ref"}.

Following a full clinical evaluation, each patient underwent a five‐ to seven‐day period of trial stimulation. Those reporting a positive response (\>50% imp in pain severity by a visual analog scale \[VAS\] and/or headache frequency \[HA days/mo\]) were offered a permanent implant. Over the seven‐year period between the first and last HM patients, our clinical approach to trial stimulation for all PNS patients evolved. As such, the first HM patient had initially only a trial, then permanent, ONS implanted; whereupon, as the response was inadequate, a SONS was added two months later and a full therapeutic response achieved. The second HM patient was evaluated during a period where we included two phases during the trial period for comparison---one that provided only ONS, and the other, combined ON‐SONS, and per his preference the combined system was permanently implanted. Thereafter, our approach for all patients undergoing a PNS trial for head pain has been to deliberately position leads according to where the patient reported pain and in a manner so as to optimize paresthesia concordancy. As both remaining patients were experiencing holocephalic pain, each had combined ON‐SONS systems trialed and then permanently implanted.

The operative procedures have been described in our previous reports [31](#ner12267-bib-0031){ref-type="ref"}, [38](#ner12267-bib-0038){ref-type="ref"}. Essentially, in the permanent procedure lead terminal arrays were positioned subcutaneously over both the supraorbital and occipital nerves (Fig. [1](#ner12267-fig-0001){ref-type="fig"}), whereupon the lead bodies were passed subcutaneously and connected to an implantable pulse generator (IPG). The IPGs in the first two patients were implanted in their upper gluteal regions. Seeking to ease tension on the leads and thus help rectify problems with lead migration, the IPGs in the subsequent three patients were implanted in the upper chest wall. Systems used included either an Eon with quadripolar leads (St. Jude Medical Inc., Plano, TX, USA), or a Precision Spectra with octopolar leads (Boston Scientific, Valencia, CA, USA). Postoperatively, the patients were evaluated on a regular basis for approximately two months and intermittently thereafter.

![Radiograph demonstrating positions of occipital and supraorbital quadripolar neurostimulator leads.](NER-18-297-g001){#ner12267-fig-0001}

Based on chart reviews and clinical evaluations the following pre‐implant clinical scales were assessed---headache frequency (HA days/month) and severity (VAS), frequency of hemiplegia (hemiplegic episodes/month), headache medication usage (number of different HA medications/day), and functional impairment (Migraine Disability Assessment \[MIDAS\] score). The self‐administered MIDAS score is the most frequently used disability instrument in migraine research, and its reliability and validity have been extensively documented [39](#ner12267-bib-0039){ref-type="ref"}, [40](#ner12267-bib-0040){ref-type="ref"}, [41](#ner12267-bib-0041){ref-type="ref"}. At the conclusion of the study the patients were interviewed by the authors, either in person or by telephone, where in addition to the same pre‐implant scales, the questionnaires included queries as to which programs were preferred (ones that provided solely an occipital paresthesia or those that provided a paresthesia over both the supraorbital and occipital regions); whether or not they would recommend the therapy to others; and their overall assessment of response.

Case Reports {#ner12267-sec-0007}
============

Case 1 {#ner12267-sec-0008}
------

In September 2006 a 49‐year‐old woman presented with daily incapacitating HAs. They began as a teenager and two years prior to presentation progressed to severe daily, unilateral throbbing HAs interspersed with fleeting, knifelike pains in her eye and jaw. Flashing lights and transient paresis of her left arm were a common prodrome; significant visual loss occurred 50% of the time; and photophobia and phonophobia were common. Her neurological examination was normal, and a full diagnostic evaluation, including magnetic resonance imaging (MRI) and CT scans, was unremarkable, whereby HM was diagnosed. Medical management, which included at least nine abortive and six prophylactic medications, ultimately failed, as the HAs became incapacitating to the point of full disability (MIDAS 255), and she was forced to resign her corporate executive position. In September 2006 bilateral occipital leads were placed with moderate but on the whole, inadequate relief. With the addition of supraorbital leads in October 2006, the HAs and all neurologic symptoms, including the hemiparesis, resolved. In March 2007 an occipital lead migrated and was repositioned. In May 2014 she reported being near HA free off all daily medications. Over the immediately preceding two months she experienced HAs requiring medication only three times, and none involved hemiplegia. She had returned to full time employment and was enjoying a normal, active lifestyle (MIDAS 7).

Case 2 {#ner12267-sec-0009}
------

A 50‐year‐old gentleman presented in August 2011 with debilitating HAs. They developed three years previously and progressed to daily, severe left‐sided HAs, which were heralded by confusion and agitation and accompanied by a left hemiplegia two to three times weekly, occasional grand mal type seizures, and prolonged (up to two days) post‐HA somnolence. A full diagnostic evaluation by experienced neurologists, including an MRI scan, revealed no other causes of head pain, and HM was diagnosed. An electroencephalogram (EEG) was positive and anti‐seizure medications prescribed. Despite an extended course of medical management, which included at least seven preventatives, the problem progressed to the point of complete incapacity (MIDAS 270), as he had to sell his several businesses and became virtually bedbound. In October 2011, a combined ON‐SONS was implanted, which resulted in near complete resolution of both the HA and the hemiplegia. In August 2013 a partial recurrence of symptoms necessitated repositioning the leads, whereupon the HAs again promptly resolved. At the follow‐up evaluation in July 2014 he was near HA free while off of all daily medications. Indeed, over the preceding two months he experienced HM on only two occasions---both of which occurred when his IPG battery depleted on trips where he forgot to bring along his external charger. Otherwise, he was completely HA and hemiplegia free and had resumed a normal lifestyle, which included all family activities and the management of two companies (MIDAS 12).

Case 3 {#ner12267-sec-0010}
------

A 52‐year‐old woman with HM was referred in August 2013 for evaluation for an implanted PNS. The HAs began 15 years previously, and 3 years prior to presentation acutely progressed to incapacitating migraines. Associated findings that uniformly began at the onset of the HA included dysarthria, intermittent aphasia, and profound weakness of the left arm and leg, along with a distinct pins and needles sensation of these extremities and dense numbness limited to the hand and foot. Grand mal type seizures were occasionally associated. The HM lasted 20 min on average, and afterward she would be somnolent the rest of the day. An EEG, MRI, and MRA were normal. An extended course of medical management, which included at least nine abortives and ten preventative medications, as well as regional nerve blocks, ultimately failed. In 2013 she responded to a combined ON‐SONS, and eight months post implant she was completely HA and hemiplegia free (0 HA days/month and 0 episodes hemiplegia/month) while off all headache medications, and had returned to a normal, fully active lifestyle, which included regular swimming, volunteer work, and taking vacations with her family (MIDAS 0).

Case 4 {#ner12267-sec-0011}
------

A 35‐year‐old woman developed HAs in her mid‐twenties. In 2009 they progressed to severe, near daily, left‐sided HAs. Right‐sided weakness (two to three times a week), visual changes, and occasionally a foul odor heralded the onset, whereupon she became bed bound for the duration (commonly one to two hours), followed by prolonged somnolence for up to a day. In 2011 she came under the care of experienced neurology HA specialists, whereby a full evaluation, including MRI scan, CT angiogram, EEG and a lumbar puncture were unremarkable, and a diagnosis of HM was made. An extended course of medical management, which included at least 12 abortive and 7 preventative medications, ultimately proved unsuccessful. At presentation she was markedly impaired (MIDAS 270) due daily severe HM, despite taking ten different HA medications daily. In 2013 she responded to a combined ON‐SONS and six months later reported very good improvement (30 → 8 HA days/mo) with resumption of a near normal lifestyle (MIDAS 3) on only one daily HA (topiramate). While feeling generally weak, she had experienced no hemiplegic episodes over the immediately preceding two months.

Results {#ner12267-sec-0012}
=======

The results of the survey are summarized in Tables [3](#ner12267-tbl-0003){ref-type="table-wrap"} and [4](#ner12267-tbl-0004){ref-type="table-wrap"}. Five patients satisfied the diagnostic criteria for HM, of whom all went on to a positive trial, followed by permanent implant. While all five reported an excellent response at their first postoperative office visit, one was lost to follow‐up when she returned to her home in Puerto Rico. The remaining four completed the full study period. For these four patients, the median patient age was 50 years (range 41--60), and the median headache duration was 15 years (range 3--30). All suffered from frequent (avg 30 HA days/month), severe (avg VAS 9.5) migraines with profound motor auras (avg 7.5 hemiplegic episodes/mo), which resulted in complete incapacitation (avg MIDAS 249). Two had grand‐mal type seizures (one with positive EEG findings and one negative), and three reported prolonged post‐headache somnolence (up to one to two days). Family histories were all negative for HM. Preimplant, the average numbers of failed migraine abortive and preventative medications were 8 (range 3--12) and 7 (range 5--8) respectively, and at presentation the average number of different headache medications being taken daily was 6 (range 4--10).

###### 

Patient Characteristics Prior to Implant

  Pt   Gen   Age   HA duration (yrs)   Preventatives (no)   HA sev (VAS)   HA freq (HA day/mo)   Neuro symptoms
  ---- ----- ----- ------------------- -------------------- -------------- --------------------- ----------------------------------------
  1    F     49    \>30                5                    10             30                    Hem, FL, Sc, LOC
  2    M     50    3                   7                    10             30                    Hem, Dys, Ap, PN, Nm, Sz, PS, LOC, PCn
  3    F     52    15                  6                    8              30                    Hem, FD, Dys, PN, FL, Sz, PS, PVr
  4    F     35    10                  8                    10             30                    Hem, FD, Dys, UBV, FO, PS

All visual and tactile sensory symptoms were unilateral and began at onset of HA or preceded the HA by less than 1 hour.

All had symptoms ipsilateral to HA, except Pt 4, who had a left sided HA but right hemiplegia and other neuro symptoms.

Preventatives---number of preventative medications tried and failed over pre‐implant.

Hem, hemiplegia; FD, facial droop; AP, aphasia; Dys, dysarthria; UBV, unilateral blurred vision; FL, flickering lights; PN, pins & needles; Nm, numbness; FO, foul odor; Sz, seizures; PS, prolonged post HA somnolence; LOC, loss of consciousness; PCn, prodrome confusion; PVr, prodrome vertigo.
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###### 

Clinical Outcome Scales

  Pt    HA day/mo   VAS   Hemiplegia/mo   MIDAS   No daily medications                                                       
  ----- ----------- ----- --------------- ------- ---------------------- ----- ----- ------ ----- ----- --- ----- --- ------ -----
  1     30          1                     10      8                            4     0            270   5         4   0      
  2     30          1     10              5       10                     1     270   2      4     0                          
  3     30          0     8               0       8                      0     270   5      10    0                          
  4     30          8     10              8       8                      0     250   10     7     1                          
  Avg   30          2.5   92%             9.5     5.3                    44%   7.5   0.25   96%   249   6   98%   6   0.25   96%

Hemiplegia/Mo---number of migraine‐associated hemiplegic episodes/mo.

The first 2 patients received St. Jude Eon systems with quadripolar leads. The last 2 received Boston Scientific Precision Spectra systems with octopolar leads. Our impression was that both systems produced equivalent therapeutic results.
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At the final evaluation, the remaining four participants had been with their systems for an average of 35 months (range 6 to 92) and reported an average 92% improvement in HA frequency (30 to 2.5 HA days/month); a 44% improvement in intensity (VAS 9.5 to 5.3); and near complete resolution of their motor auras (0--1 hemiplegic episode/mo) with resultant commensurate functional improvement (\>98% improvement in MIDAS). Three no longer required any routine daily headache medications, and the other was down to only 1 daily med. They all used their stimulator continuously and employed only combined ON‐SONS stimulation programs, as ONS alone was inadequate. Each was pleased with the results and would recommend the procedure. The two patients with documented grand mal type seizures reported no further seizures following their PNS implants.

The first two patients received St. Jude Eon systems with quadripolar lead, and the last three received Boston Scientific Precision Spectra systems with octopolar leads. Our impression was that both systems produced equivalent therapeutic results.

Adverse events included lead migrations in the first two patients, noting resumption of a full therapeutic response upon repositioning of the leads.

Discussion {#ner12267-sec-0013}
==========

Hemiplegic migraine remains a burden to the patient and society, as it is commonly resistant to medical management, which noting some debate over the use of triptans, otherwise follows the general approach as to other migraine types [2](#ner12267-bib-0002){ref-type="ref"}. As the motor auras are often the most debilitating aspect of the illness, their management has received particular attention; however, given the rarity of HM (prevalence 0.005%), the reports are anecdotal and include four case series involving treatment with either intranasal ketamine, verapamil, or a combination of lamotrigine and sodium valproate [2](#ner12267-bib-0002){ref-type="ref"}, [42](#ner12267-bib-0042){ref-type="ref"}, [43](#ner12267-bib-0043){ref-type="ref"}, [44](#ner12267-bib-0044){ref-type="ref"}, [45](#ner12267-bib-0045){ref-type="ref"}. The lamotrigine/valproate series reported a decrease in the frequency of hemiplegic episodes in a family of three patients, including one who went from 12 hemiplegic episodes/mo to complete resolution (0 hemiplegic episodes/mo) [42](#ner12267-bib-0042){ref-type="ref"}.

Recently, PNS has been offered as a potential treatment, and since 2006 there have been two case reports of motor auras responding to combined neurostimulation [31](#ner12267-bib-0031){ref-type="ref"}, [32](#ner12267-bib-0032){ref-type="ref"}. In our series all four patients, pre‐implant were suffering from frequent hemiplegic episodes (avg 7.5 hemiplegic episodes/mo). Post‐implant all described virtual resolution of the episodes at their first post‐permanent office visit, and this response continued. At their final evaluations, three of the four patients were completely hemiplegia free over the immediately preceding two months and the other reported only two episodes over the same period (avg 0.25 hemiplegic episodes/month). But, even in that case the episodes occurred only when he twice left town without his recharger, and the battery depleted. Viewed differently, over the two months immediately preceding their last evaluation, all four patients were completely hemiplegia free so long as their implanted systems were functioning and on.

In addition to its clinical importance, any responsiveness of motor auras to PNS would suggest a potential mechanistic role for the cerebral cortex in PNS therapeutic action. This thesis should be considered within the context of our current understanding of the functional neuroanatomy related to potential mechanisms of PNS action, as well as migraine pathogenesis. With respect to the PNS mechanisms, interest has largely centered on two regions---the trigeminocervical complex (TCC) and higher CNS centers. The caudal trigeminal nucleus and portions of the upper three cervical dorsal horns form the TCC. Nociceptive afferents from both the trigeminal nerve and the occipital nerves partially converge on the same second order neurons in the TCC and thus to a final common pathway to higher centers for cephalic nociception and modulation [46](#ner12267-bib-0046){ref-type="ref"}, [47](#ner12267-bib-0047){ref-type="ref"}, [48](#ner12267-bib-0048){ref-type="ref"}, [49](#ner12267-bib-0049){ref-type="ref"}. These findings were originally intended as evidence for the TCC being the anatomic substrate underlying the well‐accepted clinical phenomena of headache pain referral; for example, the common clinical observation of pain initially localized over the occiput, e.g., occipital neuralgia, yet over time spreads to the frontal regions [48](#ner12267-bib-0048){ref-type="ref"}, [49](#ner12267-bib-0049){ref-type="ref"}. In 2003 however Popeney and Aló assigned potential mechanistic value to the TCC as regards PNS, when they suggested that TCC convergence might help explain why a paresthesia perceived over the C2‐3 distribution may be mechanistically related to pain relief perceived over the distant trigeminal network [25](#ner12267-bib-0025){ref-type="ref"}.

More recent evidence, however, suggests than any putative mechanistic role for the TCC be reconsidered. First, Bartsch and Goadsby\'s work, which is often cited as foundational for a TCC site of PNS action, actually found only nociceptive specific neurons in the TCC (corresponding to A~d~ and C fiber input) [47](#ner12267-bib-0047){ref-type="ref"}, [48](#ner12267-bib-0048){ref-type="ref"}, [49](#ner12267-bib-0049){ref-type="ref"}. They specifically found no low threshold mechanoreceptors that would correlate to fibers responsible for vibratory sensation (A~B~ afferents) [49](#ner12267-bib-0049){ref-type="ref"}. Now, while it is generally accepted that cervical A~B~ afferents do synapse in various dorsal lamina of the cervical cord, we can find no direct empiric evidence for their convergence with trigeminal nociceptor afferents. In other words, while there is empiric evidence for trigeminal nociceptive and occipital nociceptive fiber convergence, there is none for trigeminal nociceptive and occipital non‐nociceptive (vibratory sensation) convergence. This is not to rule out the possibility of such convergence; rather, it is to indicate the want of direct evidence.

Further, TCC convergence cannot explain the reports documenting a therapeutic response to trigeminal stimulation alone for pain perceived over a trigeminal region, e.g., SONS for supraorbital pain [28](#ner12267-bib-0028){ref-type="ref"}, [29](#ner12267-bib-0029){ref-type="ref"}, [30](#ner12267-bib-0030){ref-type="ref"}, [36](#ner12267-bib-0036){ref-type="ref"}, [50](#ner12267-bib-0050){ref-type="ref"}, [51](#ner12267-bib-0051){ref-type="ref"}, [52](#ner12267-bib-0052){ref-type="ref"}, [53](#ner12267-bib-0053){ref-type="ref"}, [54](#ner12267-bib-0054){ref-type="ref"}, [55](#ner12267-bib-0055){ref-type="ref"}, [56](#ner12267-bib-0056){ref-type="ref"}, [57](#ner12267-bib-0057){ref-type="ref"}. The reason for this is that while trigeminal nociceptive afferents do synapse in the caudal trigeminal nucleus, the trigeminal A~B~ fibers do not; rather, they synapse in the distinct principal trigeminal nucleus [58](#ner12267-bib-0058){ref-type="ref"}. Thus, a TCC convergence mechanism is problematic, as the fibers simply do not synapse in the same TCC nuclei.

Additionally, recent clinical findings also challenge a role for the TCC. Magis found increased nociceptive‐specific blink reflexes in a study on ONS and cluster headaches as clinical evidence against a TCC role in PNS therapeutic action [59](#ner12267-bib-0059){ref-type="ref"}. Therefore, when considering the available experimental findings, we suggest that the mechanistic role for the TCC as currently formulated be reconsidered.

On the other hand, there is mounting evidence supporting a mechanistic role for higher CNS centers. In 2003 Matharu presented positron emission tomography (PET) scan evidence for such a role for some of these centers, including the cuneus, pulvinar, and anterior cingulate cortex [27](#ner12267-bib-0027){ref-type="ref"}. Others have since reported similar or consistent PET and functional MRI findings [59](#ner12267-bib-0059){ref-type="ref"}, [60](#ner12267-bib-0060){ref-type="ref"}. Notably, however, none have posited a role for the somatosensory cortex, which is interesting as it is the one anatomic locus that is accepted as a site of nociceptive and non‐nociceptive convergence. As an illustrative example, a patient with occipital neuralgia treated with an ONS experiences both pain and ONS‐induced vibratory sensation over the same region of the occiput, which indicates that the corresponding occipital region of the sensory homunculus is involved in both sensations; that is, both occipital nociceptive and non‐nociceptive afferents (vibratory sense) converge on the same region of the cortex.

With respect to migraine pathogenesis, it is now understood that the cortex plays a central role, as it is the locus for cortical spreading depression (CSD), which is generally accepted as the physiologic substrate to the clinical auras (visual, motor, etc.) that precede the actual headache [61](#ner12267-bib-0061){ref-type="ref"}. CSD is a wave of cortical cellular depolarization followed by prolonged quiescence, which typically begins at the visual cortex and then propagates rostrally over the sensorimotor cortical areas. Animal studies have demonstrated CSD activation of meningeal nociceptors and then central trigeminovascular neurons in the spinal trigeminal nucleus, which is one of the presumed mechanistic pathways related to migraine [61](#ner12267-bib-0061){ref-type="ref"}, [62](#ner12267-bib-0062){ref-type="ref"}, [63](#ner12267-bib-0063){ref-type="ref"}. The cortex is therefore central to the genesis of both the pain and hemiplegia due HM.

Could PNS‐related stimulation of the cortex in some fashion effectively block the spreading depression wave front? There is indeed some early experimental evidence for this, as in 2010 Kovacs presented functional MRI findings in a patient treated with ONS that demonstrated depression of the motor (M1), sensory (S1 & S2), and visual (V1) cortical areas, which are exactly the same cortical regions involved with CSD [60](#ner12267-bib-0060){ref-type="ref"}.

Thus, the currently accepted model for CSD indicates that the cortex is functionally integral to the generation of both the pain and the motor auras of HM. As CSD is viewed causally as the immediate precursor to the motor aura, then any therapy that impacts the motor aura would suggest that the cortex be included as possibly mechanistically significant. In that regard, our findings of dramatic responses of the motor auras in all of these patients are consistent with the CSD model. As the evidence is indeed early, these suggestions stand as speculations, yet ones that can be tested by appropriate controlled studies, likely involving neuroimaging techniques.

A final aspect of our study that deserves attention is that of paresthesia concordancy; in this case the application of combined ON‐SONS to holocephalic pain due HM, a therapeutic approach that relates to the potential relationship between paresthesia concordancy and clinical outcome. Preceding this report, five others have described similar positive results with concordant, combined PNS (three on ON‐SONS; two on ON‐Auriculotemporal Stimulation) [31](#ner12267-bib-0031){ref-type="ref"}, [32](#ner12267-bib-0032){ref-type="ref"}, [33](#ner12267-bib-0033){ref-type="ref"}, [35](#ner12267-bib-0035){ref-type="ref"}, [36](#ner12267-bib-0036){ref-type="ref"}. Support for this approach is provided by direct comparisons of the concordant and non‐concordant paresthesia groupings of extant outcome studies, which are summarized in Tables [1](#ner12267-tbl-0001){ref-type="table-wrap"} and [2](#ner12267-tbl-0002){ref-type="table-wrap"} (updated tables from an earlier report of ours) [7](#ner12267-bib-0007){ref-type="ref"}. Taken together, the reports on ONS for CM (non‐concordant paresthesia) average to a 46% response rate, while those on ON‐SONS therapy (concordant paresthesia) to 81%. The difference is highlighted when the results of the benchmark Boston Scientific, St. Jude, and Medtronic controlled studies on non‐concordant ONS for CM are scrutinized, as they all actually found limited or no response. The Boston Scientific team found no significant therapeutic response, and Medtronic\'s reported 39% response rate was based only on a 30% improvement in the VAS as the definition of responder vs. the historical standard of \>50% improvement [18](#ner12267-bib-0018){ref-type="ref"}, [21](#ner12267-bib-0021){ref-type="ref"}. The St. Jude study failed to demonstrate significant improvement in its primary endpoint (VAS) but did find a 48% response rate applying the historical 50% standard [19](#ner12267-bib-0019){ref-type="ref"}, [20](#ner12267-bib-0020){ref-type="ref"}. This difference in response rates supports an approach for a concordant paresthesia, and evidence adduced in this report is consistent with that database, as all of our patients were treated with concordant, combined ON‐SONS, noting further that they preferred programs that provided both occipital and supraorbital stimulation against those that provided occipital stimulation alone.

Limitations of our study include the small sample size, the lack of a diary, lack of genetic testing, and an open‐label, non‐randomized structure. While a placebo effect cannot be completely excluded, given the uniform dramatic responses across all patients and for the duration of their implants, we feel that there is likely minimal placebo effect.

Conclusions {#ner12267-sec-0014}
===========

These case reports offer preliminary evidence suggesting a potential for combined ON‐SONS as a therapy for patients suffering from hemiplegic migraine. The evidence is sufficient to warrant prospective, controlled studies of sufficient power to appropriately evaluate the therapeutic potential.
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